Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States; Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.
Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States; Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.
Pathol Res Pract. 2020 Jun;216(6):152967. doi: 10.1016/j.prp.2020.152967. Epub 2020 Apr 19.
Prostate cancer is managed by surgery, androgen deprivation and cytotoxic chemotherapy. Targeted therapy is emerging as an important pillar in cancer therapeutics, however, efficacy in prostate cancer has been limited. Eph-ephrin is a novel pathway that is upregulated in prostate cancer and promotes the initiation and progression of cancer. The aim of this study was to determine the immunohistochemical expression of ephrinB2 in prostate adenocarcinoma.
A tissue microarray comprising of prostate adenocarcinoma of different grade groups was stained with a monoclonal anti-ephrinB2 antibody (Abcam, AB201512). The tumor and endothelial cells expressing the ephrinB2 positivity were noted. The statistical analysis was performed to determine the difference in expression based on grade groups and the TNM stage.
EphrinB2 was expressed in 40 out of 72 cases (55.5 %) of prostate adenocarcinoma and was predominantly negative in the normal prostatic tissue. There was no significant difference in the expression of ephrinB2 in various grade groups (p = 0.7) or stages (p = 0.6).
EphrinB2 is expressed in a significant number of prostate adenocarcinoma regardless of grade and stage. Hence, there is a potential to target this molecule in the low-grade tumors with localized disease as well as high grade, high volume tumors with metastatic disease.
前列腺癌的治疗方法包括手术、去势治疗和细胞毒性化疗。靶向治疗作为癌症治疗的一个重要支柱正在兴起，然而，其在前列腺癌中的疗效有限。Eph-ephrin 是一种在前列腺癌中上调的新型途径，可促进癌症的发生和发展。本研究旨在确定 EphrinB2 在前列腺腺癌中的免疫组织化学表达。
使用单克隆抗 EphrinB2 抗体（Abcam，AB201512）对包含不同分级组的前列腺腺癌组织微阵列进行染色。记录表达 EphrinB2 阳性的肿瘤细胞和内皮细胞。进行统计学分析，以确定基于分级组和 TNM 分期的表达差异。
EphrinB2 在 72 例前列腺腺癌中的 40 例（55.5%）中表达，在正常前列腺组织中主要为阴性。EphrinB2 的表达在不同分级组（p=0.7）或分期（p=0.6）之间无显著差异。
EphrinB2 在大量前列腺腺癌中表达，无论分级和分期如何。因此，有可能针对低分级、局限性肿瘤以及高分级、高体积、转移性肿瘤中的这种分子进行靶向治疗。
